首页> 外文期刊>The lancet oncology >Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
【24h】

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

机译:来那度胺联合地塞米松与高危阴燃性多发性骨髓瘤(QuiRedex)患者的观察:一项随机,对照,3期试验的长期随访

获取原文
获取原文并翻译 | 示例
           

摘要

Background The standard of care for smouldering multiple myeloma is observation. We did the QuiRedex study to compare early treatment with lenalidomide plus dexamethasone with observation in patients with high-risk smouldering multiple myeloma. Here we report the long-term follow-up results of the trial.
机译:背景技术闷烧多发性骨髓瘤的治疗标准是观察。我们进行了QuiRedex研究,比较了来那度胺和地塞米松的早期治疗与高危阴燃多发性骨髓瘤患者的观察结果。在这里,我们报告了该试验的长期随访结果。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号